Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) released its quarterly earnings data on Friday. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.12, Zacks reports. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%. The firm had revenue of $3.22 billion during the quarter, compared to the consensus estimate of $3.02 billion.
Astellas Pharma Stock Down 1.7 %
Shares of ALPMY traded down $0.17 during mid-day trading on Thursday, hitting $9.91. The company's stock had a trading volume of 67,192 shares, compared to its average volume of 221,948. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 0.39. The company's 50-day moving average is $9.62 and its 200-day moving average is $10.03. Astellas Pharma has a 52-week low of $8.37 and a 52-week high of $13.14. The firm has a market capitalization of $17.93 billion, a price-to-earnings ratio of -45.04 and a beta of 0.31.
About Astellas Pharma
(
Get Free Report)
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
See Also
Before you consider Astellas Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.
While Astellas Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
